EGFR and non-small cell lung carcinoma: In this study, 53.55% of NSCLC patients in our cohort had EGFR alternations, most of which had been well developed as actionable variants, such as L858R, exon 19 del, exon 20‐ins, L861Q, G719X, S768I, and T790 M (Figure 2A).